State of Wyoming Acquires 4,337 Shares of Hologic, Inc. $HOLX

Key Points

• The State of Wyoming increased its holdings in Hologic, Inc. by 59.1% in the first quarter, acquiring an additional 4,337 shares for a total of 11,672 shares worth $721,000.
• Hologic reported a quarterly EPS of $1.08, exceeding analysts' estimates of $1.05, and achieved revenue of $1.02 billion, up 1.2% year-over-year.
• Current analyst ratings for Hologic include one "Strong Buy," eight "Buy," and eight "Hold," with a consensus price target of $78.00.

State of Wyoming lifted its holdings in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 59.1% in the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 11,672 shares of the medical equipment provider's stock after acquiring an additional 4,337 shares during the quarter. State of Wyoming's holdings in Hologic were worth $721,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Zions Bancorporation National Association UT bought a new stake in Hologic in the 1st quarter valued at $34,000. Bank Julius Baer & Co. Ltd Zurich acquired a new position in Hologic in the 1st quarter valued at $42,000. Raiffeisen Bank International AG acquired a new position in Hologic in the 4th quarter valued at $49,000. Allworth Financial LP raised its holdings in Hologic by 46.0% in the 1st quarter. Allworth Financial LP now owns 686 shares of the medical equipment provider's stock valued at $40,000 after acquiring an additional 216 shares in the last quarter. Finally, Larson Financial Group LLC raised its holdings in Hologic by 6,016.7% in the 1st quarter. Larson Financial Group LLC now owns 734 shares of the medical equipment provider's stock valued at $45,000 after acquiring an additional 722 shares in the last quarter. 94.73% of the stock is currently owned by institutional investors.

Hologic Price Performance

Hologic stock opened at $67.12 on Friday. The company has a debt-to-equity ratio of 0.52, a quick ratio of 2.81 and a current ratio of 3.55. Hologic, Inc. has a 52 week low of $51.90 and a 52 week high of $84.39. The stock has a market capitalization of $14.93 billion, a P/E ratio of 27.85, a price-to-earnings-growth ratio of 2.42 and a beta of 0.49. The stock has a fifty day moving average of $66.15 and a 200-day moving average of $62.50.

Hologic (NASDAQ:HOLX - Get Free Report) last posted its quarterly earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 EPS for the quarter, topping analysts' consensus estimates of $1.05 by $0.03. Hologic had a return on equity of 19.69% and a net margin of 13.79%.The company had revenue of $1.02 billion during the quarter, compared to analysts' expectations of $1.01 billion. During the same quarter in the previous year, the firm earned $1.06 EPS. Hologic's revenue was up 1.2% on a year-over-year basis. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. On average, sell-side analysts expect that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

HOLX has been the subject of several analyst reports. Mizuho set a $75.00 price objective on Hologic in a report on Thursday, July 31st. Morgan Stanley lifted their price objective on Hologic from $65.00 to $69.00 and gave the company an "equal weight" rating in a report on Thursday, July 31st. Citigroup raised Hologic from a "neutral" rating to a "buy" rating and lifted their price objective for the company from $60.00 to $80.00 in a report on Wednesday, July 9th. Stephens dropped their price objective on Hologic from $77.00 to $70.00 and set an "overweight" rating for the company in a report on Tuesday, May 13th. Finally, Raymond James Financial reaffirmed an "outperform" rating and issued a $71.00 price objective (down from $90.00) on shares of Hologic in a report on Friday, May 2nd. One analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and eight have assigned a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $78.00.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.